# SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints

- Source: PR Newswire M&A
- Published: 2026-11-02T19:02:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/simplaafy-study-of-the-watchman-flx-pro-left-atrial-appendage-closure-device-meets-primary-endpoints-302926809.html
- Canonical: https://groundlevelnews.com/story/simplaafy-study-of-the-watchman-flx-pro-left-atrial-appendage-closure--03c354/

Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens MARLBOROUGH, Mass. and SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX)...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._